Family-owned Italian biopharmaceutical group Dompe Farmaceutici is considering a listing of its shares as it looks to focus more on its biotech business and treating specific diseases.
“In 3-4 years we could consider a flotation perhaps in the U.S.,” Chief Executive Sergio Dompe said.
Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger – or buying a listed business – in the United States, one of the company’s key markets.
The CEO said private equity firms, as well as some European and U.S. industrial players, had made contact with a view to buying the company.
“I told them not to bother since I will never sell,” he said.
Italy has a thriving pharmaceutical sector. But it is fragmented and analysts believe it could benefit from consolidation.
In June, family-controlled Recordati was snapped up by a consortium of investment funds controlled by CVC Capital Partners in a deal worth about 3 billion euros ($3.4 billion).
Dompe Farmaceutici, headquartered in Milan, employs around 800 people and had sales last year of 250 million euros.
Six patients dead after New Jersey virus outbreak
Earlier this year the U.S. Food and Drug Administration approved its new product based on cenegermin – the first drug for the treatment of rare eye disease neurotrophic keratitis.
Dompe, who hopes to be able to market the new treatment in China, said the new cenegermin-based drug was a game changer that could help boost margins over time and support investments in research and development.
“I’m looking to make this company a pharmaceutical biotech business with a focus on particular diseases,” Dompe said. ($1 = 0.8786 euros)
By Stephen Jewkes
Source: Reuters
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
